BioRestorative Therapies (NASDAQ:BRTX) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS

BioRestorative Therapies (NASDAQ:BRTX) announced its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.22, Zacks reports. BioRestorative Therapies had a negative return on equity of 93.89% and a negative net margin of 2,697.08%. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.30 million.

BioRestorative Therapies Stock Performance

BRTX traded down $0.02 during mid-day trading on Thursday, reaching $1.53. The stock had a trading volume of 27,286 shares, compared to its average volume of 768,548. The stock has a market capitalization of $10.55 million, a P/E ratio of -1.03 and a beta of 63.40. BioRestorative Therapies has a 52 week low of $1.03 and a 52 week high of $3.67. The firm’s fifty day simple moving average is $1.63 and its two-hundred day simple moving average is $1.60.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm raised their price objective on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.